Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fomivirsen · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Fomivirsen sodium | DRUG | - |
| Ganciclovir | DRUG | - |
Inclusion Criteria Patients must have: * AIDS. * CMV retinitis that is not adequately controlled (previously diagnosed patients with smoldering CMV retinitis or those with active CMV retinitis borders on indirect ophthalmoscopy). * No more than one previous progression of CMV retinitis. Exclusion...
Fomivirsen is an investigational small molecule being developed for cytomegalovirus retinitis, an eye infection that can occur in people with HIV. It is administered intravitreally, meaning directly into the eye. The drug is currently in Phase 2 clinical development and is not approved by the FDA.
Fomivirsen is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in patients with cytomegalovirus retinitis.
Fomivirsen is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA for commercial use. The drug is being studied for the treatment of cytomegalovirus retinitis, and its clinical trials have been completed.
Fomivirsen has been studied in two completed Phase 2 clinical trials. One trial, NCT00002156, enrolled 194 participants and compared intravitreal Fomivirsen plus ganciclovir versus ganciclovir alone for cytomegalovirus retinitis. The other trial, NCT00002356, evaluated the safety and effectiveness of Fomivirsen in patients with AIDS and CMV of the eyes.
Yes, Fomivirsen is also known as ISIS 2922. Clinical trial records refer to the drug by this alternative name, for example in the trial titled 'A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis.'